135 related articles for article (PubMed ID: 9292710)
1. Immunocytochemical detection of P-glycoprotein in the management of malignant effusions.
Athanassiadou P; Athanassiades P; Petrakakou E; Zerva C; Mavrikakis M
J Cancer Res Clin Oncol; 1997; 123(8):456-60. PubMed ID: 9292710
[TBL] [Abstract][Full Text] [Related]
2. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers.
Veneroni S; Zaffaroni N; Daidone MG; Benini E; Villa R; Silvestrini R
Eur J Cancer; 1994; 30A(7):1002-7. PubMed ID: 7946563
[TBL] [Abstract][Full Text] [Related]
3. Intracavitary doxorubicin in malignant effusions.
Tattersall MH; Fox RM; Newlands ES; Woods RL
Lancet; 1979 Feb; 1(8112):390. PubMed ID: 85046
[No Abstract] [Full Text] [Related]
4. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer.
Chung HC; Rha SY; Kim JH; Roh JK; Min JS; Lee KS; Kim BS; Lee KB
Breast Cancer Res Treat; 1997 Jan; 42(1):65-72. PubMed ID: 9116319
[TBL] [Abstract][Full Text] [Related]
5. Intracavitary chemotherapy.
Markman M
Crit Rev Oncol Hematol; 1985; 3(3):205-33. PubMed ID: 2412719
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic effect of Jin Long capsule combined with neoadjuvant chemotherapy on invasive breast cancer and the expression change of multidrug resistance proteins].
Yang TY; Yi W; Wen J; Gan CY; Yang YC; Dai M
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):118-123. PubMed ID: 30862141
[No Abstract] [Full Text] [Related]
7. Nucleoside transporters are widely expressed in ovarian carcinoma effusions.
Bock AJ; Dong HP; Tropé CG; Staff AC; Risberg B; Davidson B
Cancer Chemother Pharmacol; 2012 Feb; 69(2):467-75. PubMed ID: 21822668
[TBL] [Abstract][Full Text] [Related]
8. Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
Davidson B; Goldberg I; Givant-Horwitz V; Nesland JM; Berner A; Bryne M; Risberg B; Kopolovic J; Kristensen GB; Tropé CG; van de Putte G; Reich R
Am J Clin Pathol; 2002 Feb; 117(2):225-34. PubMed ID: 11863219
[TBL] [Abstract][Full Text] [Related]
9. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer.
Linn SC; Honkoop AH; Hoekman K; van der Valk P; Pinedo HM; Giaccone G
Br J Cancer; 1996 Jul; 74(1):63-8. PubMed ID: 8679460
[TBL] [Abstract][Full Text] [Related]
10. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.
Schlüter B; Gerhards R; Strumberg D; Voigtmann R
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1389-400. PubMed ID: 20217132
[TBL] [Abstract][Full Text] [Related]
11. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy.
Vargas-Roig LM; Gago FE; Tello O; Martin de Civetta MT; Ciocca DR
Int J Cancer; 1999 Apr; 84(2):129-34. PubMed ID: 10096243
[TBL] [Abstract][Full Text] [Related]
12. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin.
Ostrowski MJ
Cancer; 1986 Feb; 57(4):721-7. PubMed ID: 2417681
[TBL] [Abstract][Full Text] [Related]
13. Intracavitary thiotepa in malignant pleural and peritoneal effusions.
Andersen AP; Brincker H
Acta Radiol Ther Phys Biol; 1968 Oct; 7(5):369-78. PubMed ID: 4981030
[No Abstract] [Full Text] [Related]
14. [Treatment of metastatic breast cancer].
Yahalom J; Biran S; Sulkes A
Harefuah; 1986 Jul; 111(1-2):8-11. PubMed ID: 2430868
[No Abstract] [Full Text] [Related]
15. Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin.
Maiche AG
Anticancer Drugs; 1994 Jun; 5(3):305-8. PubMed ID: 7522646
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of malignant pleural effusions by intracavitary injection of mixture of 5FU, cyclophosphamide, mitomycin C, bleomycin and thioinosine].
Asakura H
Nihon Gan Chiryo Gakkai Shi; 1973 Jun; 8(2):107-12. PubMed ID: 4125905
[No Abstract] [Full Text] [Related]
17. Ex vivo reversal of chemoresistance by tariquidar (XR9576).
Di Nicolantonio F; Knight LA; Glaysher S; Whitehouse PA; Mercer SJ; Sharma S; Mills L; Prin A; Johnson P; Charlton PA; Norris D; Cree IA
Anticancer Drugs; 2004 Oct; 15(9):861-9. PubMed ID: 15457126
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer].
Wagner T
Onkologie; 1984 Feb; 7(1):22-6. PubMed ID: 6369203
[TBL] [Abstract][Full Text] [Related]
19. Intracavitary bleomycin in the management of malignant effusions.
Paladine W; Cunningham TJ; Sponzo R; Donavan M; Olson K; Horton J
Cancer; 1976 Nov; 38(5):1903-8. PubMed ID: 62609
[TBL] [Abstract][Full Text] [Related]
20. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
